Ozempic is a prescription injection approved by the FDA to treat type 2 diabetes in adults. First approved in 2017, it has since gained two additional indications: reducing the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes and heart disease, and slowing kidney disease progression in adults with type 2 diabetes and chronic kidney disease. All three uses require a diagnosis of type 2 diabetes.
How Ozempic Works
Ozempic contains semaglutide, which mimics a hormone your gut naturally releases after eating called GLP-1. Your body breaks down natural GLP-1 within minutes, but semaglutide is engineered to last much longer, which is why it only needs to be injected once a week.
When semaglutide activates GLP-1 receptors, several things happen. It signals your pancreas to release more insulin, but only when blood sugar is elevated, which lowers the risk of dangerous blood sugar drops. It also suppresses glucagon, a hormone that tells your liver to dump stored sugar into the bloodstream. On top of that, it slows how quickly food leaves your stomach, which blunts the blood sugar spike after meals. Semaglutide also acts on appetite centers in the brain, reducing hunger and increasing the feeling of fullness after eating.
Type 2 Diabetes Management
Ozempic’s primary use is improving blood sugar control in adults with type 2 diabetes, alongside diet and exercise. In the SUSTAIN clinical trial program, a 1.0 mg weekly dose reduced A1C (a measure of average blood sugar over roughly three months) by 1.5% to 1.8% after 30 to 56 weeks. For context, an A1C drop of even 1% is considered clinically meaningful and significantly lowers the risk of diabetes-related complications.
Ozempic is delivered as a once-weekly injection under the skin, typically in the abdomen, thigh, or upper arm. You start at 0.25 mg weekly for four weeks. That starting dose isn’t meant to control blood sugar; it’s there to let your body adjust and minimize side effects. After four weeks, the dose increases to 0.5 mg. If blood sugar still isn’t well controlled after at least another four weeks, your doctor may raise it to the maximum dose of 1 mg (or 2 mg for some patients).
Cardiovascular Protection
For people who have both type 2 diabetes and established heart disease, Ozempic carries a second FDA-approved indication: reducing the risk of heart attack, stroke, and cardiovascular death. This approval is based on the SUSTAIN-6 trial, which followed over 3,200 patients for about two years.
Patients taking semaglutide had a 26% lower risk of the combined outcome of cardiovascular death, nonfatal heart attack, or nonfatal stroke compared to placebo. The benefit was most striking for stroke: nonfatal stroke occurred in 1.6% of the semaglutide group versus 2.7% in the placebo group, a 39% relative reduction. Heart attack rates were also lower (2.9% vs. 3.9%), though that difference didn’t reach statistical significance on its own. Rates of cardiovascular death were similar between the two groups, meaning the protection came primarily from preventing nonfatal events.
Kidney Disease in Type 2 Diabetes
Ozempic’s newest approved use, based on the FLOW trial, targets adults who have both type 2 diabetes and chronic kidney disease. Kidney damage is one of the most common and serious complications of diabetes, and it often progresses silently for years.
In the FLOW trial, semaglutide reduced the risk of major kidney events by 24% compared to placebo. Those events included kidney failure requiring dialysis or transplant, a 50% or greater decline in kidney filtration, and death from kidney or cardiovascular causes. Looking at the kidney-specific components alone, the risk was 21% lower. Cardiovascular death was also 29% lower in the semaglutide group. The trial was actually stopped early because the benefits were clear enough that continuing to give some patients a placebo was no longer considered ethical.
Weight Loss and Off-Label Use
Ozempic is not FDA-approved for weight loss. That distinction belongs to Wegovy, which contains the same active ingredient (semaglutide) but is available at a higher maximum dose of 2.4 mg compared to Ozempic’s 2 mg. Wegovy is specifically approved for weight management in adults and children 12 and older, for reducing cardiovascular risk in adults with obesity and heart disease, and most recently for treating a serious liver condition called metabolic-associated steatohepatitis (MASH) in adults with moderate to advanced liver scarring.
That said, Ozempic is widely prescribed off-label for weight loss because semaglutide’s appetite-suppressing effects are the same regardless of which brand name is on the pen. The weight loss happens because the drug reduces hunger and slows digestion, leading people to eat less without feeling deprived. Doctors sometimes prescribe Ozempic off-label when Wegovy is unavailable or when insurance won’t cover it.
Common Side Effects
The most frequent side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and stomach pain. These tend to be worst during the dose-increase phases and often improve over several weeks as your body adjusts. Indigestion, bloating, and burping are also common. Less frequent but reported side effects include headache, fatigue, dizziness, and acid reflux.
For people with type 2 diabetes who also take insulin or certain other diabetes medications, low blood sugar (hypoglycemia) is a potential risk and something to monitor, especially early in treatment.
Who Should Not Take Ozempic
Ozempic carries a boxed warning, the FDA’s most serious safety label, about the risk of thyroid tumors. In animal studies, semaglutide caused thyroid C-cell tumors. Whether this translates to humans isn’t fully known, but as a precaution, Ozempic is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (a specific type of thyroid cancer) or a condition called Multiple Endocrine Neoplasia syndrome type 2.
Cost Without Insurance
Ozempic’s self-pay list price is $349 per month for the 0.25 mg, 0.5 mg, or 1 mg doses, and $499 per month for the 2 mg dose. Novo Nordisk, the manufacturer, offers an introductory price of $199 per month for uninsured or self-pay patients new to the 0.25 mg and 0.5 mg doses. With commercial insurance, copays vary widely depending on your plan’s formulary. Many insurers cover Ozempic for type 2 diabetes but deny claims when it’s prescribed off-label for weight management alone.